Feasibility of Mass Cytometry Proteomic Characterisation of Circulating Tumour Cells in Head and Neck Squamous Cell Carcinoma for Deep Phenotyping

Overview

Journal Br J Cancer

Specialty Oncology

Date 2023 Sep 21

PMID 37735243

Authors

Karl Payne

Jill Brooks

Nikolaos Batis

Naeem Khan

Mohammed El-Asrag

Paul Nankivell

Hisham Mehanna

Graham Taylor

Affiliations

Soon will be listed here.

Abstract

Background: Circulating tumour cells (CTCs) are a potential cancer biomarker, but current methods of CTC analysis at single-cell resolution are limited. Here, we describe high-dimensional single-cell mass cytometry proteomic analysis of CTCs in HNSCC.

Methods: Parsortix microfluidic-enriched CTCs from 14 treatment-naïve HNSCC patients were analysed by mass cytometry analysis using 41 antibodies. Immune cell lineage, epithelial-mesenchymal transition (EMT), stemness, proliferation and immune checkpoint expression was assessed alongside phosphorylation status of multiple signalling proteins. Patient-matched tumour gene expression and CTC EMT profiles were compared. Standard bulk CTC RNAseq was performed as a baseline comparator to assess mass cytometry data.

Results: CTCs were detected in 13/14 patients with CTC counts of 2-24 CTCs/ml blood. Unsupervised clustering separated CTCs into epithelial, early EMT and advanced EMT groups that differed in signalling pathway activation state. Patient-specific CTC cluster patterns separated into immune checkpoint low and high groups. Patient tumour and CTC EMT profiles differed. Mass cytometry outperformed bulk RNAseq to detect CTCs and characterise cell phenotype.

Discussion: We demonstrate mass cytometry allows high-plex proteomic characterisation of CTCs at single-cell resolution and identify common CTC sub-groups with potential for novel biomarker development and immune checkpoint inhibitor treatment stratification.

Citing Articles

Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.

Bergmann L, Afflerbach A, Yuan T, Pantel K, Smit D Semin Immunopathol. 2025; 47(1):14.

PMID: 39893314 PMC: 11787191. DOI: 10.1007/s00281-025-01042-z.

Post-Translational Modifications of Proteins Orchestrate All Hallmarks of Cancer.

Bruno P, Arshad A, Gogu M, Waterman N, Flack R, Dunn K Life (Basel). 2025; 15(1).

PMID: 39860065 PMC: 11766951. DOI: 10.3390/life15010126.

The impact of elective cervical lymph node treatment on the tumour immune response in head and neck squamous cell carcinoma: time for a change in treatment strategy?.

Payne K, Nenclares P, Schilling C BJC Rep. 2024; 2(1):68.

PMID: 39516703 PMC: 11524052. DOI: 10.1038/s44276-024-00095-1.

Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications.

Salu P, Reindl K Cancers (Basel). 2024; 16(6).

PMID: 38539545 PMC: 10969710. DOI: 10.3390/cancers16061213.

A New Era of Integration between Multiomics and Spatio-Temporal Analysis for the Translation of EMT towards Clinical Applications in Cancer.

Fonseca Teixeira A, Wu S, Luwor R, Zhu H Cells. 2023; 12(23).

PMID: 38067168 PMC: 10706093. DOI: 10.3390/cells12232740.

References

Payne K, Pugh M, Brooks J, Batis N, Taylor G, Nankivell P . Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2020; 21(21). PMC: 7662307. DOI: 10.3390/ijms21218229. View

Apostolou P, Ntanovasilis D, Papasotiriou I . Evaluation of a simple method for storage of blood samples that enables isolation of circulating tumor cells 96 h after sample collection. J Biol Res (Thessalon). 2017; 24:11. PMC: 5613324. DOI: 10.1186/s40709-017-0068-9. View

Pastushenko I, Blanpain C . EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2018; 29(3):212-226. DOI: 10.1016/j.tcb.2018.12.001. View

Chen J, Zhou J, Lu J, Xiong H, Shi X, Gong L . Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. BMC Cancer. 2014; 14:15. PMC: 3893437. DOI: 10.1186/1471-2407-14-15. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

Sinkala E, Sollier-Christen E, Renier C, Rosas-Canyelles E, Che J, Heirich K . Profiling protein expression in circulating tumour cells using microfluidic western blotting. Nat Commun. 2017; 8:14622. PMC: 5376644. DOI: 10.1038/ncomms14622. View

Bhatia S, Wang P, Toh A, Thompson E . New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression. Front Mol Biosci. 2020; 7:71. PMC: 7190792. DOI: 10.3389/fmolb.2020.00071. View

Tada H, Takahashi H, Ida S, Nagata Y, Chikamatsu K . Epithelial-Mesenchymal Transition Status of Circulating Tumor Cells Is Associated With Tumor Relapse in Head and Neck Squamous Cell Carcinoma. Anticancer Res. 2020; 40(6):3559-3564. DOI: 10.21873/anticanres.14345. View

Sapio L, Salzillo A, Ragone A, Illiano M, Spina A, Naviglio S . Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update. Cancers (Basel). 2020; 12(11). PMC: 7693618. DOI: 10.3390/cancers12113166. View

10.

Jarnuczak A, Najgebauer H, Barzine M, Kundu D, Ghavidel F, Perez-Riverol Y . An integrated landscape of protein expression in human cancer. Sci Data. 2021; 8(1):115. PMC: 8065022. DOI: 10.1038/s41597-021-00890-2. View

11.

Benoy I, Elst H, van Dam P, Scharpe S, Van Marck E, Vermeulen P . Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. Clin Chem Lab Med. 2006; 44(9):1082-7. DOI: 10.1515/CCLM.2006.210. View

12.

Akan P, Alexeyenko A, Costea P, Hedberg L, Werne Solnestam B, Lundin S . Comprehensive analysis of the genome transcriptome and proteome landscapes of three tumor cell lines. Genome Med. 2012; 4(11):86. PMC: 3580420. DOI: 10.1186/gm387. View

13.

Visal T, den Hollander P, Cristofanilli M, Mani S . Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?. Br J Cancer. 2022; 127(2):173-184. PMC: 9296521. DOI: 10.1038/s41416-022-01768-9. View

14.

Wang W, Peng J, Li X, Wang A, Bie Y, Shi L . Survival Mechanisms and Influence Factors of Circulating Tumor Cells. Biomed Res Int. 2018; 2018:6304701. PMC: 6236925. DOI: 10.1155/2018/6304701. View

15.

Chen Y, Li S, Li W, Yang R, Zhang X, Ye Y . Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Sci Rep. 2019; 9(1):7084. PMC: 6506548. DOI: 10.1038/s41598-019-43572-1. View

16.

Pantel K, Alix-Panabieres C . Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation. J Immunother Cancer. 2022; 10(12). PMC: 9756199. DOI: 10.1136/jitc-2022-005615. View

17.

Samatar A, Poulikakos P . Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014; 13(12):928-42. DOI: 10.1038/nrd4281. View

18.

Abouleila Y, Onidani K, Ali A, Shoji H, Kawai T, Lim C . Live single cell mass spectrometry reveals cancer-specific metabolic profiles of circulating tumor cells. Cancer Sci. 2018; 110(2):697-706. PMC: 6361580. DOI: 10.1111/cas.13915. View

19.

Payne K, Brooks J, Taylor G, Batis N, Noyvert B, Pan Y . Immediate Sample Fixation Increases Circulating Tumour Cell (CTC) Capture and Preserves Phenotype in Head and Neck Squamous Cell Carcinoma: Towards a Standardised Approach to Microfluidic CTC Biomarker Discovery. Cancers (Basel). 2021; 13(21). PMC: 8583049. DOI: 10.3390/cancers13215519. View

20.

Jie X, Zhang X, Xu C . Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications. Oncotarget. 2017; 8(46):81558-81571. PMC: 5655309. DOI: 10.18632/oncotarget.18277. View